2 active not recruiting, 2 completed. 4 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 4 | Active not recruiting 2, Completed 2 |
| Phase 2 | 2 | Active not recruiting 1, Completed 1 |
Follow Solid Neoplasms: new trials by email Literature Review of Solid Neoplasms trials Research Report on Solid Neoplasms
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Dazostinag as Single Agent and Dazostinag in Combination With Pembrolizumab in Adults With Advanced or Metastatic Solid Tumors Dazostinag, Pembrolizumab, Platinum - Solid Neoplasms | Phase 1 / Phase 2 | Completed | Takeda | 248 | 2020-07-22 | 2026-10-22 |
| A Study of E7389 Liposomal Formulation (E7389-LF) Plus Nivolumab in Participants With Solid Tumor E7389-LF, Nivolumab - Solid Neoplasms | Phase 1 / Phase 2 | Active not recruiting | Eisai Co., Ltd. | 125 | 2019-09-05 | 2026-10-13 |
| A Study of E7386 in Participants With Advanced Solid Tumor Including Colorectal Cancer (CRC) E7386 - Solid Neoplasms, Colorectal Neoplasms | Phase 1 | Active not recruiting | Eisai Co., Ltd. | 70 | 2019-03-05 | 2026-02-27 |
| Study of MK-7162 in Combination With Pembrolizumab (MK-3475) in Adult Participants With Advanced Solid Tumors (MK-7162-002) MK-7162, Pembrolizumab - Solid Neoplasms | Phase 1 | Completed | Merck Sharp & Dohme LLC | 33 | 2017-12-06 | 2021-11-15 |
Adrenocortical Carcinoma (1) · Carcinoma, Hepatocellular (1) · Colorectal Neoplasms (1) · Desmoid Tumors (1) · Digestive System Neoplasms (1) · Gastro-enteropancreatic neuroendocrine tumor (1) · Neoplasms (1)
Adenocarcinoma (1) · Adrenal Cortex Diseases (1) · Adrenal Cortex Neoplasms (1) · Adrenal Gland Diseases (1) · Adrenal Gland Neoplasms (1) · Carcinoma (1) · Colonic Diseases (1) · Digestive System Diseases (1) · Endocrine Gland Neoplasms (1) · Endocrine System Diseases (1) · Fibroma (1) · Gastrointestinal Diseases (1) · Gastrointestinal Neoplasms (1) · Intestinal Diseases (1) · Intestinal Neoplasms (1)
pembrolizumab (2) · E-7386 (1) · Fluorouracil (1) · Nivolumab (1) · Platinum (1)
Eisai Co., Ltd. (2) · Merck Sharp & Dohme LLC (1) · Takeda (1)
Japan (3) · Canada (2) · Israel (2) · United States (2) · Austria (1) · China (1) · France (1) · Poland (1) · Puerto Rico (1) · South Korea (1) · Switzerland (1) · United Kingdom (1)
PMID 36923556, PMID 38295160, PMID 39516370, PMID 41888610
2017 (1), 2023 (1)